Application of Bortezomib to the Treatment of Multiple Myeloma

Multiple myeloma is a plasma cell malignancy,characterized by clonal expansion of plasma cells in bone marrow,and monoclonal immunoglobulin or the fragment(M protein) produced by plasma cells,together with a wide range of dissolved bone lesions and clinical manifestations such as anemia,infection,impaired renal function. Bortezomib is a new type of proteasome inhibitors,which can fight against multiple myeloma through new mechanism. Bortezomib,as a single agent or being combined with other conventional chemotherapy agent,has positive therapeutic effect on patients with newly diagnosed or relapsed/refractory multiple myeloma. In this article,the clinical application of bortezomib to the treatment of multiple myeloma is reviewed.